1126 related articles for article (PubMed ID: 15520202)
81. Protease inhibitors interfere with the transforming growth factor-beta-dependent but not the transforming growth factor-beta-independent pathway of tumor cell-mediated immunosuppression.
Huber D; Philipp J; Fontana A
J Immunol; 1992 Jan; 148(1):277-84. PubMed ID: 1727872
[TBL] [Abstract][Full Text] [Related]
82. GDF-15 contributes to proliferation and immune escape of malignant gliomas.
Roth P; Junker M; Tritschler I; Mittelbronn M; Dombrowski Y; Breit SN; Tabatabai G; Wick W; Weller M; Wischhusen J
Clin Cancer Res; 2010 Aug; 16(15):3851-9. PubMed ID: 20534737
[TBL] [Abstract][Full Text] [Related]
83. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
Harthun NL; Weaver AM; Brinckerhoff LH; Deacon DH; Gonias SL; Slingluff CL
J Immunother; 1998 Mar; 21(2):85-94. PubMed ID: 9551359
[TBL] [Abstract][Full Text] [Related]
84. Development and characterization of DP-153, a nontumorigenic prostatic cell line that undergoes malignant transformation by expression of dominant-negative transforming growth factor beta receptor type II.
Song K; Cornelius SC; Danielpour D
Cancer Res; 2003 Aug; 63(15):4358-67. PubMed ID: 12907605
[TBL] [Abstract][Full Text] [Related]
85. Suppression of tumor metastasis by blockade of transforming growth factor beta signaling in bone marrow cells through a retroviral-mediated gene therapy in mice.
Shah AH; Tabayoyong WB; Kundu SD; Kim SJ; Van Parijs L; Liu VC; Kwon E; Greenberg NM; Lee C
Cancer Res; 2002 Dec; 62(24):7135-8. PubMed ID: 12499244
[TBL] [Abstract][Full Text] [Related]
86. TGF-beta is not involved in early phase growth inhibition of keratinocytes by 1alpha,25(OH)2vitamin D3.
Shirakata Y; Ueno H; Hanakawa Y; Kameda K; Yamasaki K; Tokumaru S; Yahata Y; Tohyama M; Sayama K; Hashimoto K
J Dermatol Sci; 2004 Oct; 36(1):41-50. PubMed ID: 15488704
[TBL] [Abstract][Full Text] [Related]
87. Pioglitazone induces apoptosis in human vascular smooth muscle cells from diabetic patients involving the transforming growth factor-beta/activin receptor-like kinase-4/5/7/Smad2 signaling pathway.
Ruiz E; Redondo S; Gordillo-Moscoso A; Tejerina T
J Pharmacol Exp Ther; 2007 May; 321(2):431-8. PubMed ID: 17267584
[TBL] [Abstract][Full Text] [Related]
88. Compound Astragalus and Salvia miltiorrhiza extract inhibits cell invasion by modulating transforming growth factor-beta/Smad in HepG2 cell.
Liu X; Yang Y; Zhang X; Xu S; He S; Huang W; Roberts MS
J Gastroenterol Hepatol; 2010 Feb; 25(2):420-6. PubMed ID: 19793165
[TBL] [Abstract][Full Text] [Related]
89. Reduction of TGF-beta activity abrogates growth promoting tumor cell-cell interactions in vivo.
Theodorescu D; Caltabiano M; Greig R; Rieman D; Kerbel RS
J Cell Physiol; 1991 Sep; 148(3):380-90. PubMed ID: 1655815
[TBL] [Abstract][Full Text] [Related]
90. Activin A inhibits growth-inhibitory signals by TGF-beta1 in differentiated human endometrial adenocarcinoma cells.
Tanaka T; Toujima S; Umesaki N
Oncol Rep; 2004 Apr; 11(4):875-9. PubMed ID: 15010888
[TBL] [Abstract][Full Text] [Related]
91. SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility.
Hjelmeland MD; Hjelmeland AB; Sathornsumetee S; Reese ED; Herbstreith MH; Laping NJ; Friedman HS; Bigner DD; Wang XF; Rich JN
Mol Cancer Ther; 2004 Jun; 3(6):737-45. PubMed ID: 15210860
[TBL] [Abstract][Full Text] [Related]
92. Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft.
Bandyopadhyay A; López-Casillas F; Malik SN; Montiel JL; Mendoza V; Yang J; Sun LZ
Cancer Res; 2002 Aug; 62(16):4690-5. PubMed ID: 12183427
[TBL] [Abstract][Full Text] [Related]
93. The expression of TGF-beta receptors in human atherosclerosis: evidence for acquired resistance to apoptosis due to receptor imbalance.
McCaffrey TA; Du B; Fu C; Bray PJ; Sanborn TA; Deutsch E; Tarazona N; Shaknovitch A; Newman G; Patterson C; Bush HL
J Mol Cell Cardiol; 1999 Sep; 31(9):1627-42. PubMed ID: 10471347
[TBL] [Abstract][Full Text] [Related]
94. MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastoma.
Grzmil M; Morin P; Lino MM; Merlo A; Frank S; Wang Y; Moncayo G; Hemmings BA
Cancer Res; 2011 Mar; 71(6):2392-402. PubMed ID: 21406405
[TBL] [Abstract][Full Text] [Related]
95. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes.
Kehrl JH; Roberts AB; Wakefield LM; Jakowlew S; Sporn MB; Fauci AS
J Immunol; 1986 Dec; 137(12):3855-60. PubMed ID: 2878044
[TBL] [Abstract][Full Text] [Related]
96. Transforming growth factor-beta 1 (TGF beta 1) enhances apoptosis in human papillomavirus type 16-immortalized human ectocervical epithelial cells.
Rorke EA; Jacobberger JW
Exp Cell Res; 1995 Jan; 216(1):65-72. PubMed ID: 7529191
[TBL] [Abstract][Full Text] [Related]
97. Release from quiescence of primitive human hematopoietic stem/progenitor cells by blocking their cell-surface TGF-beta type II receptor in a short-term in vitro assay.
Fortunel N; Hatzfeld J; Kisselev S; Monier MN; Ducos K; Cardoso A; Batard P; Hatzfeld A
Stem Cells; 2000; 18(2):102-11. PubMed ID: 10742382
[TBL] [Abstract][Full Text] [Related]
98. Inhibition of transforming growth factor-beta1 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress.
Kirshner J; Jobling MF; Pajares MJ; Ravani SA; Glick AB; Lavin MJ; Koslov S; Shiloh Y; Barcellos-Hoff MH
Cancer Res; 2006 Nov; 66(22):10861-9. PubMed ID: 17090522
[TBL] [Abstract][Full Text] [Related]
99. A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells.
Bandyopadhyay A; Zhu Y; Cibull ML; Bao L; Chen C; Sun L
Cancer Res; 1999 Oct; 59(19):5041-6. PubMed ID: 10519421
[TBL] [Abstract][Full Text] [Related]
100. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4.
Brockmann MA; Papadimitriou A; Brandt M; Fillbrandt R; Westphal M; Lamszus K
Clin Cancer Res; 2003 Oct; 9(12):4578-85. PubMed ID: 14555533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
